Approved for two
years (change will be required for finalization of SADR rule)
consistent with clarification in FDA memo of 4-29- 03.
Inventory as of this Action
Requested
Previously Approved
07/31/2005
07/31/2005
05/31/2003
24,720
0
17,406
576,593
0
268,803
0
0
0
The AER requirements enable FDA to
take actions necessary for the protection of the public health in
response to reports of adverse experiences related to licensedx
biological products. The recordkeeping requirements serve
preventative and remedial purposes by requesting accountability and
traceability in each step from the manufacture to distribution and
recall of products and by enabling FDA to perform meaningful
inspections. Respondents to this collection of information are
manufacturers of biological products.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.